Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 12/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196799 | 0.82 | CCR3 (0.50) | EPHX2MEN1TSHRKMT2AKDM4E | |
| SCHEMBL4196629 | 0.82 | KMT2A (0.48) | POLBMEN1KMT2A | |
| SCHEMBL4197445 | 0.82 | KMT2A (0.48) | POLBMEN1KMT2A | |
| SCHEMBL4195095 | 0.82 | KMT2A (0.48) | POLBMEN1KMT2A | |
| SCHEMBL4197557 | 0.81 | NPC1 (0.54) | POLBEPHX2MEN1KMT2AKDM4E | |
| SCHEMBL4192548 | 0.79 | KMT2A (0.47) | POLBEPHX2MEN1TSHRKMT2A | |
| SCHEMBL4196843 | 0.79 | EPHX1 (0.52) | MEN1KMT2AGSK3BKDM4E | |
| SCHEMBL4193053 | 0.79 | TP53 (0.52) | POLBMEN1KMT2AKDM4E | |
| SCHEMBL4204460 | 0.79 | NPY1R (0.42) | — | |
| SCHEMBL4193564 | 0.79 | HTT (0.56) | POLBEPHX2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | claimed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | claimed |
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | disclosed |
| US-8076370-B2 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-13 | — | — | US | disclosed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215764-A1 | Antimicrobial agents | TUFM, RPS17, HARS1 | GCK 725/4885POLB 215/4885EPHX2 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.